Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
- Author
- ReachMD
- Published
- Wed 18 Dec 2024
- Episode Link
- http://reachmd.com/programs/cme/advances-in-masldmash-treating-the-liver-the-disease-and-the-patient-chairs-perspective/24278/
CME credits: 0.25
Valid until: 18-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-masldmash-treating-the-liver-the-disease-and-the-patient-chairs-perspective/24278/
Valid until: 18-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-masldmash-treating-the-liver-the-disease-and-the-patient-chairs-perspective/24278/
MASLD/MASH is a serious, chronic, progressive disease that will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. The good news is we now have a recently approved liver-directed therapy. Tune in to ensure you know how to effectively identify and treat MASLD/MASH in your patients.
=